{"url_path":"/sec/mlab/10-k/2026/item-2","section_key":"item-2","section_title":"Item 2 Properties**","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/724004/0000724004-26-000047-index.html","accession_number":"0000724004-26-000047","cik":"0000724004","ticker":"MLAB","issuer_name":"MESA LABORATORIES INC /CO/","edgar_url":"https://www.sec.gov/Archives/edgar/data/724004/0000724004-26-000047-index.html","primary_entity_key":"0000724004","primary_entity_name":"MESA LABORATORIES INC /CO/"},"word_count":133,"has_tables":true,"body_markdown":"**Item 2. Properties**\n\n \n\nAs of March 31, 2026, we owned two facilities, both of which are material to our business: a facility in Lakewood, Colorado used by our Calibration Solutions division, and a facility in Bozeman, Montana used by our Sterilization and Disinfection Control division. We also lease multiple properties used by our Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics divisions. Significant leased locations include our Biopharmaceutical Development facility in Sweden, a facility used by our Clinical Genomics division in the United States, and facilities in Germany used primarily by our Sterilization and Disinfection Control division. Our owned and leased facilities are used for manufacturing and distribution, research and development, sales and marketing, and administration activities. We believe our properties are suitable and adequate to carry out our business."}